- Home
- CJJD vs APLM Comparison
CJJD vs APLM Comparison
Compare CJJD & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CJJD
- APLM
- Stock Information
- Founded
- CJJD 2003
- APLM 2016
- Country
- CJJD China
- APLM United States
- Employees
- CJJD N/A
- APLM N/A
- Industry
- CJJD Retail-Drug Stores and Proprietary Stores
- APLM Blank Checks
- Sector
- CJJD Consumer Staples
- APLM Finance
- Exchange
- CJJD Nasdaq
- APLM Nasdaq
- Market Cap
- CJJD 10.9M
- APLM 12.3M
- IPO Year
- CJJD N/A
- APLM N/A
- Fundamental
- Price
- CJJD $1.38
- APLM $7.02
- Analyst Decision
- CJJD
- APLM Strong Buy
- Analyst Count
- CJJD 0
- APLM 2
- Target Price
- CJJD N/A
- APLM $425.00
- AVG Volume (30 Days)
- CJJD 21.9K
- APLM 7.4K
- Earning Date
- CJJD 03-19-2025
- APLM 03-04-2025
- Dividend Yield
- CJJD N/A
- APLM N/A
- EPS Growth
- CJJD N/A
- APLM N/A
- EPS
- CJJD N/A
- APLM N/A
- Revenue
- CJJD $147,126,392.00
- APLM $2,101,000.00
- Revenue This Year
- CJJD N/A
- APLM N/A
- Revenue Next Year
- CJJD N/A
- APLM N/A
- P/E Ratio
- CJJD N/A
- APLM N/A
- Revenue Growth
- CJJD N/A
- APLM 70.54
- 52 Week Low
- CJJD $1.29
- APLM $6.38
- 52 Week High
- CJJD $4.40
- APLM $80.50
- Technical
- Relative Strength Index (RSI)
- CJJD 38.69
- APLM 37.88
- Support Level
- CJJD $1.30
- APLM $6.70
- Resistance Level
- CJJD $1.49
- APLM $7.60
- Average True Range (ATR)
- CJJD 0.07
- APLM 0.70
- MACD
- CJJD 0.01
- APLM -0.03
- Stochastic Oscillator
- CJJD 30.00
- APLM 22.30
About CJJD China Jo-Jo Drugstores Inc. (Cayman Islands)
China Jo-Jo Drugstores Inc is a retailer and distributor of pharmaceutical products. The company's operating segments include Retail drugstores, Online Pharmacy, and Drug wholesale. Retail drugstores segment sells prescription and over-the-counter medicines, TCM, dietary supplements, medical devices, and sundry items to retail customers. The online pharmacy segment sells drugs through third-party platforms such as Alibaba's Tmall, JD.com, and Amazon.com. It generates maximum revenue from the Retail drugstores segment.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.